Effects of Pharmaceutical Intervention on Cardiovascular Risk

Special Issue Editors


E-Mail Website
Guest Editor
Cardiology Rehabilitation Unit, IRCCS San Raffaele, 00163 Rome, Italy
Interests: hypercholesterolemia; cardiovascular prevention; cardiac rehabilitation; heart failure

E-Mail Website
Guest Editor
1. Department of Human Science and Promotion of Quality of Life, San Raffaele Open University, 00163 Rome, Italy
2. Cardiovascular Unit, San Raffaele IRCCS, 00163 Rome, Italy
Interests: hypertension; chronic heart failure; atrial fibrillation; exercise training; sport medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cardiovascular diseases are the leading cause of death worldwide, being responsible for about 30% of total mortality. Considering that cardiovascular diseases are largely preventable, prioritizing preventative measures is fundamentally important to reduce their impact on public health. The current approach to the prevention of cardiovascular diseases includes the promotion a healthy and physically active lifestyle as well as the administration of drugs for treating cardiovascular risk factors such as hypertension, hypercholesterolemia, or diabetes. Although effective and safe risk factor treatments have been developed in the last few decades, there is still much work to be conducted in this area. Risk factors are often poorly treated and therapeutic goals are often disregarded, even in patients considered to be at high cardiovascular risk. There is, therefore, a need to develop new drugs and optimize the use of medications currently available. At the same time, it is necessary to develop therapeutic strategies suited to the patient's risk profile, with the aim of pursuing an increasingly personalized approach, avoiding overtreatments, and minimizing drug-related side effects.

This Special Issue welcomes manuscripts focused on (1) investigating the effects of new drugs and new treatment strategies on cardiovascular risk factors; (2) optimizing the pharmacological management of patients belonging to different risk categories; and (3) assessing patients' adherence to primary prevention drugs and studying strategies for improving adherence to treatments.

Dr. Giuseppe Marazzi
Prof. Dr. Giuseppe Caminiti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular risk factors
  • primary prevention
  • hypercholesterolemia
  • diabetes
  • hypertension

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 556 KiB  
Article
Addition of Bempedoic Acid to Statin–Ezetimibe versus Statin Titration in Patients with High Cardiovascular Risk: A Single-Centre Prospective Study
by Giuseppe Marazzi, Giuseppe Caminiti, Marco Alfonso Perrone, Giuseppe Campolongo, Luca Cacciotti, Domenico Mario Giamundo, Ferdinando Iellamo, Paolo Severino, Maurizio Volterrani and Giuseppe Rosano
J. Cardiovasc. Dev. Dis. 2024, 11(9), 286; https://doi.org/10.3390/jcdd11090286 - 14 Sep 2024
Viewed by 636
Abstract
Reducing levels of low-density lipoprotein cholesterol (LDL-C) below recommended thresholds is a core component of cardiovascular prevention strategies. We hypothesized that the addition of bempedoic acid to patients already on statin–ezetimibe therapy was more effective than titrating the statin dose in reducing LDL-C. [...] Read more.
Reducing levels of low-density lipoprotein cholesterol (LDL-C) below recommended thresholds is a core component of cardiovascular prevention strategies. We hypothesized that the addition of bempedoic acid to patients already on statin–ezetimibe therapy was more effective than titrating the statin dose in reducing LDL-C. The study enrolled 120 patients at high cardiovascular risk and with LDL-C above 70 mg/dL. They were randomly divided into two groups: the bempedoic acid (BA) group, taking bempedoic acid in addition to statin plus ezitimibe, and the statin titration (ST) group, including patients who doubled the dose of statin. At 12 weeks, the BA group presented a more significant decrease in LDL-C compared to the ST group (−22.9% vs. 7.5% p 0.002). The total cholesterol decreased significantly in the BA group compared to ST (−14.8% vs.−4.7%; p 0.013) No significant between-group changes in HDL and triglycerides occurred. At 12 weeks, the number of patients who reached LDL-C lower than 70 mg/dL was 38 (63%) in the BA group versus 22 (37%) in the ST group (between groups, p 0.034). In the BA group, the LDL-lowering effect of bempedoic acid was similar between patients taking atorvastatin and rosuvastatin. No side effects occurred during the follow up period. In conclusion, the addition of bempedoic acid to statin–ezetimibe combined treatment was more effective than doubling the dose of statin in reducing LDL-C levels and increased the number of patients reaching the LDL-C goal. Full article
(This article belongs to the Special Issue Effects of Pharmaceutical Intervention on Cardiovascular Risk)
Show Figures

Figure 1

Back to TopTop